Surrozen : Investor Presentation January 2022

The Wnt Company - Targeted Regeneration

Legal Disclaimers

Forward-lookingstatements. This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward- looking statements generally are accompanied by words such as "will," "expect," "continue," "plan," "target," "potential," "milestone," "opportunities," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

These forward-looking statements include, but are not limited to, statements regarding Surrozen's discovery, research and development activities, in particular its development plans for its product candidates SZN-1326,SZN-043,SZN-413 and potential future candidates, including anticipated clinical development timelines, and the potential for such product candidates to be used to treat human disease. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of Surrozen. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to SZN-1326,SZN-043,SZN-413, and potential future drug candidates; Surrozen's ability to identify, develop and commercialize drug candidates; Surrozen's ability to advance SZN-1326,SZN-043,SZN-413, or other future product candidates into, and successfully complete, preclinical studies and clinical studies; the effects of the ongoing coronavirus (COVID-19) pandemic or other infectious diseases and natural disasters on Surrozen's business; Surrozen's ability to effectively manage growth and expand business operations; and those factors discussed in Surrozen's Quarterly Report on Form 10-Q under the heading "Risk Factors" and other documents Surrozen has filed, or will file, with the U.S. Securities and Exchange Commission. If any of these risks materialize or the underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen's expectations, plans, or forecasts of future events and views as of the date of this presentation. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen's assessments of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

© 2022 Surrozen, Inc.

2

From Wnt Gene Discovery to the Clinic

Scientific	Biologic	Therapeutic
Discovery	Validation	Transformation

	Surrozen
	founded by The
1st Wnt gene	Column Group in
discovered	collaboration with
(Roel Nusse, Harold	preeminent Wnt
Varmus)	biologists
1982	2016
2013	2017
Breakthrough	Breakthrough
Prize in Life	Prize in Life
Sciences awarded	Sciences awarded
to Hans Clevers for	to Roel Nusse for
"describing the	"pioneering
role of Wnt	research on the
signaling in tissue	Wnt pathway"
stem cells"

First Wnt

modulating antibody approved, Amgen's Evenity (romosuzumab) for osteoporosis

2019

Surrozen progresses targeted Wnt therapeutics platform; expect to initiate FIH trials

2022+

2020

Publication of Surrozen's SWAP and SWEETS antibody platform discoveries

© 2022 Surrozen, Inc.

3

What is Wnt Biology?

Wnt Signaling Essential to Many Cell and Tissue Types

Fundamental Signal Transduction Biology

Wnt pathway central to:

• Regulating stem cell renewal, proliferation & differentiation
• Regenerating tissue

Wnt proteins generate array of Wnt signaling critical for:

• Shaping tissues during development
• Maintaining tissue architecture
• Repairing injured tissue

Many Organs and Tissues Require Wnt signaling

Eye

BBB

Lung

Cochlea

Liver

Pancreas

GIKidney

© 2022 Surrozen, Inc.

4

Surrozen - Leaders in Wnt Biology

Vision

Initial focus

First in class

Lead Product

Candidates

Proprietary platform

Well positioned

Selectively target Wnt pathway to harness the body's own repair mechanism

Wnt related severe or acute diseases: GI, Liver, Ophthalmology

Proof of mechanism / biology and preclinical proof of safety for both lead candidates

Expect to initiate two clinical trials in Q3 '22

• SZN-1326: Inflammatory Bowel Disease
• SZN-043:Severe Liver Disease
• SZN-413:Ophthalmology

Unparalleled capabilities; demonstrated preclinical POC for several programs

$135M cash balance

© 2022 Surrozen, Inc.

Cash balance as of 9/30/21

5